Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Estradiol Patch Compounding Legal Status: FDA Rules, 503A/503B, and What Patients Should Know

By
Published Updated Last reviewed
8 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Compounded estradiol / Not FDA-approved; FDA does not verify safety, effectiveness or quality before marketing [1]
  • FDA position / For patients whose needs cannot be met by an FDA-approved drug [1]
  • Approved patches / Climara, Vivelle-Dot, Minivelle and generics, applied once or twice weekly [3][4]
  • Availability / FDA says patches remain available and supply has nearly doubled over the past year [2]
  • Boxed warning / Climara and Vivelle-Dot labels still carry the older endometrial cancer, cardiovascular, dementia and breast cancer warning [3][4]
  • Oversight / State boards oversee state-licensed pharmacies; FDA inspects registered outsourcing facilities [1]

Is compounded estradiol legal?

Federal law addresses compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, by a physician, and in an outsourcing facility [1]. Outsourcing facilities were established in 2013 by the Drug Quality and Security Act. They register with FDA, are inspected on a risk-based schedule, and must meet current good manufacturing practice (CGMP) requirements [1]. Drugs compounded by a pharmacist in a state-licensed pharmacy or by a physician under the federal compounding conditions are not subject to those CGMP requirements, although FDA does conduct surveillance and for-cause inspections of such pharmacies [1].

FDA says poor compounding practices can produce contamination or a drug with too much or too little active ingredient [1]. FDA-approved estradiol tablets and patches exist [3].

What FDA-approved estradiol patches exist?

Estradiol is an FDA-approved prescription estrogen sold as generic oral tablets and as once-weekly or twice-weekly transdermal patches, including Climara, Vivelle-Dot, Minivelle and generics [3][4]. The Climara approval listing covers 0.025, 0.0375, 0.05, 0.06, 0.075 and 0.1 mg per 24 hours and lists Menostar at 0.014 mg per 24 hours [5].

In an update dated September 3, 2026, FDA said some patients have had trouble readily accessing their usual patches because of increased demand. It said availability of brands may vary by pharmacy or location, that estradiol patches remain available, and that supply of FDA-approved patches has nearly doubled over the past year [2].

Do the patch labels still carry the old boxed warning?

Yes, on the labels checked. On November 10, 2025, FDA asked makers of menopausal hormone therapy to remove boxed-warning language on cardiovascular disease, breast cancer and probable dementia, but to keep the endometrial cancer boxed warning on systemic estrogen-alone products [6]. On February 12, 2026 it approved the first six updated labels (Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva), and estradiol patches are not on that list [7][8].

The Climara and Vivelle-Dot labels still carry the older boxed warning titled Endometrial Cancer, Cardiovascular Disorders, Probable Dementia and Breast Cancer [3][4].

Frequently asked questions

Is compounded estradiol FDA-approved?
No. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed. FDA says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug [1].
Can patients still get FDA-approved estradiol patches?
FDA says yes. Its September 3, 2026 update says some patients have had trouble getting their usual patch because of increased demand, that brands may vary by pharmacy or location, and that estradiol patches remain available. It also says supply of FDA-approved patches has nearly doubled over the past year [2].
Do estradiol patch labels still have a boxed warning?
Yes. The Climara and Vivelle-Dot labels still carry a boxed warning covering endometrial cancer, cardiovascular disorders, probable dementia and breast cancer, and estradiol patches are not among the six products whose labeling FDA updated on February 12, 2026 [3][4][8].
What separates a state-licensed compounding pharmacy from an outsourcing facility?
State boards of pharmacy have primary responsibility for day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities. Outsourcing facilities register with FDA, are inspected by FDA on a risk-based schedule, and their drugs must meet current good manufacturing practice [1].

References

  1. Compounding and the FDA: Questions and Answers | FDA. Compounding and the FDA: Questions and Answers | FDA
  2. FDA Update on Estradiol Transdermal Patch Availability | FDA. FDA Update on Estradiol Transdermal Patch Availability | FDA
  3. U.S. National Library of Medicine, DailyMed. Climara estradiol transdermal system (Bayer) prescribing information. Climara estradiol transdermal system (Bayer) label
  4. U.S. National Library of Medicine, DailyMed. Vivelle-Dot estradiol transdermal system (Sandoz) prescribing information. Vivelle-Dot estradiol transdermal system (Sandoz) label
  5. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  6. FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies | FDA. FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies | FDA
  7. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products | FDA. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products | FDA
  8. Menopausal Hormone Therapies with Updated Prescribing Information | FDA. Menopausal Hormone Therapies with Updated Prescribing Information | FDA
Evidence overview for Estradiol Patch Compounding Legal Status: FDA Rules, 503A/503B, and What Patients Should Know